|
| 2007 Annual Index |
|
| January 1; 49 (1251) : 1-4 |
| Sitagliptin (Januvia) for Type 2 Diabetes; |
| Oral Oxymorphone (Opana) |
|
| January 15; 49 (1252) : 5-8 |
| Low-Dose Doxycycline (Oracea) for Rosacea; |
| Dasatinib (Sprycel) for CML and Ph+ ALL; |
| Tdap, DTaP Mix-Ups |
|
| January 29; 49 (1253) : 9-12 |
| Pioglitazone/Glimepiride (Duetact) for Diabetes; |
| Telbivudine (Tyzeka) for Chronic Hepatitis B; |
| Clarification: Hand Hygiene and CDAD |
|
|
|
| February 12; 49 (1254) : 13-16 |
| Continuous Glucose Monitoring; |
| Angeliq for Treatment of Menopausal Symptoms |
|
| February 26; 49 (1255) : 17-20 |
| Proton Pump Inhibitors for GERD in Children; |
| Two New Drugs for Renal Cell Carcinoma; |
| In Brief: Femcon Fe: A Chewable Oral Contraceptive |
|
|
|
| March 12; 49 (1256) : 21-24 |
| Paliperidone (Invega) for Schizophrenia; |
| Vorinostat (Zolinza) for Cutaneous T-cell Lymphoma |
|
| March 26; 49 (1257) : 25-28 |
| Once-Daily Mesalamine (Lialda) for Ulcerative Colitis; |
| Pramipexole (Mirapex) for Restless Legs Syndrome |
|
|
|
| April 9; 49 (1258) : 29-32 |
| Aliskiren (Tekturna) for Hypertension; |
| Subcutaneous Immune Globulin (SCIG) |
|
| April 23; 49 (1259) : 33-36 |
| Drugs for Female Sexual Dysfunction; |
| Panitumumab (Vectibix) for Metastatic Colorectal Cancer |
|
|
|
| May 7; 49 (1260) : 37-40 |
| Erythropoietin Safety Concerns; |
| Dermal Fillers; |
| In Brief: Tegaserod (Zelnorm) Withdrawn |
|
| May 21; 49 (1261) : 41-44 |
| A New Sunscreen Agent; |
| Insulin-like Growth Factor-1 for Severe Growth Failure |
|
|
|
| June 4; 49 (1262) : 45-48 |
| Sitagliptin/Metformin (Janumet) for Type 2 Diabetes; |
| MoviPrep: A New Bowel Prep for Colonoscopy; |
| In Brief: Toxicity of Gadolinium-Based Contrast Agents |
| Correction: Panitumumab Dosage |
|
| June 18; 49 (1263) : 49-52 |
| Treatment of Lyme Disease; |
| ThermaClear for Acne; |
| In Brief: Orlistat OTC for Weight Loss |
|
|
|
| July 2; 49 (1264) : 53-56 |
| Arformoterol (Brovana) for COPD; |
| Resperate for Hypertension; |
| In Brief: Testing for Ovarian Cancer |
|
| July 16; 49 (1265) : 57-60 |
| Thiazolidinediones and Cardiovascular Disease; |
| Lisdexamfetamine Dimesylate (Vyvanse) for ADHD; |
| In Brief: Anaphylaxis with Omalizumab; |
| Addendum: Dermal Fillers |
|
| July 30; 49 (1266) : 61-64 |
| Lybrel – A Continuous Oral Contraceptive; |
| Drugs of Choice for Community-Acquired Bacterial Pneumonia; |
| Corrections: Lyme Disease |
|
|
|
| August 13; 49 (1267) : 65-68 |
| Reducing Intake of Trans Fatty Acid; |
| Probiotics |
|
| August 27; 49 (1268) : 69-72 |
| Transdermal Rotigotine (Neupro) for Parkinson's Disease; |
| Low-Dose Transdermal Estrogens; |
| Correction: Resperate |
|
|
|
| September 10; 49 (1269) : 73-76 |
| Tinidazole (Tindamax) - A New Option for Treatment of Bacterial Vaginosis; |
| Lapatinib (Tykerb) for Advanced Breast Cancer; |
| Removable Permanent Tattoo Ink |
|
| September 24; 49 (1270) : 77-80 |
| Pregabalin (Lyrica) for Fibromyalgia; |
| Fentanyl Buccal Tablet (Fentora) for Breakthrough Pain; |
| Eculizumab (Soliris) for Paroxysmal Nocturnal Hemoglobinuria |
|
|
|
|
| November 5; 49 (1273) : 89-92 |
| A Once-Yearly IV Bisphosphonate for Osteoporosis; |
| Fluticasone Furoate (Veramyst) for Allergic Rhinitis |
|
| November 19; 49 (1274) : 93-96 |
| BRCA Screening; |
| Formoterol (Perforomist) for COPD; |
| SSRIs and Osteoporosis; |
| In Brief: Varenicline (Chantix) Revisited |
|
|
|
| December 3; 49 (1275) : 97-100 |
| Levocetirizine (Xyzal) for Allergic Rhinitis and Urticaria; |
| Major Changes in Endocarditis Prophylaxis for Dental, GI and GU Procedures; |
| In Brief: Dexrazoxane for Anthracycline Extravasation; |
| Addendum: Probiotics |
|
| December 17; 49 (1276) : 101-104 |
| Two Amlodipine/ARB Combinations for Hypertension; |
| Extended-Release Cyclobenzaprine (Amrix); |
| Temsirolimus (Torisel) for Advanced Renal Cell Carcinoma; |
| Correction: Endocarditis Prophylaxis |
|
| 2007 Annual Index |
|
|
